Seelos Therapeutics Share Holder Equity 2010-2022 | SEEL
Seelos Therapeutics share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Seelos Therapeutics Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$57 |
| 2020 |
$3 |
| 2019 |
$-0 |
| 2018 |
$-5 |
| 2017 |
$4 |
| 2016 |
$-8 |
| 2015 |
$-10 |
| 2014 |
$2 |
| 2013 |
$11 |
| 2012 |
$7 |
| 2011 |
$5 |
| 2010 |
$12 |
| 2009 |
$3 |
Seelos Therapeutics Quarterly Share Holder Equity
(Millions of US $) |
| 2022-03-31 |
$46 |
| 2021-12-31 |
$57 |
| 2021-09-30 |
$73 |
| 2021-06-30 |
$83 |
| 2021-03-31 |
$25 |
| 2020-12-31 |
$3 |
| 2020-09-30 |
$7 |
| 2020-06-30 |
$4 |
| 2020-03-31 |
$7 |
| 2019-12-31 |
$-0 |
| 2019-09-30 |
$10 |
| 2019-06-30 |
$5 |
| 2019-03-31 |
$3 |
| 2018-12-31 |
$-5 |
| 2018-09-30 |
$4 |
| 2018-06-30 |
$5 |
| 2018-03-31 |
$4 |
| 2017-12-31 |
$4 |
| 2017-09-30 |
$6 |
| 2017-06-30 |
$7 |
| 2017-03-31 |
$1 |
| 2016-12-31 |
$-8 |
| 2016-09-30 |
$-8 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-7 |
| 2015-12-31 |
$-10 |
| 2015-09-30 |
$-8 |
| 2015-06-30 |
$-3 |
| 2015-03-31 |
$2 |
| 2014-12-31 |
$2 |
| 2014-09-30 |
$12 |
| 2014-06-30 |
$12 |
| 2014-03-31 |
$9 |
| 2013-12-31 |
$11 |
| 2013-09-30 |
$12 |
| 2013-06-30 |
$13 |
| 2013-03-31 |
$-1 |
| 2012-12-31 |
$7 |
| 2012-09-30 |
$24 |
| 2012-06-30 |
$17 |
| 2012-03-31 |
$20 |
| 2011-12-31 |
$5 |
| 2011-09-30 |
$6 |
| 2011-06-30 |
$6 |
| 2011-03-31 |
$12 |
| 2010-12-31 |
$12 |
| 2010-09-30 |
|
| 2010-06-30 |
$17 |
| 2010-03-31 |
$5 |
| 2009-12-31 |
$3 |
| 2009-09-30 |
$2 |
| 2009-06-30 |
$2 |
| 2009-03-31 |
$3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.065B |
$0.000B |
|
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
|
